PRF Technologies

PRF Technologies Operating Cash Flow

The Operating Cash Flow of PRF Technologies (PRFX) as of Oct 24, 2026 is -3.96 M USD. In the previous year, Operating Cash Flow was -12.62 M USD — a change of -68.66% (higher).

Operating Cash Flow

-3.96 MUSD

YoY

-68.66%

Last updated:

Operating Cash Flow of PRF Technologies is 2025 -3.96 M USD. Operating Cash Flow of PRF Technologies was 2024 -12.62 M USD. It decreases by -68.66% higher compared to the previous year.

The PRF Technologies Operating Cash Flow history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Operating Cash Flow
Date
Operating Cash Flow
Jan 1, 2018
-635,000.00 USD
Jan 1, 2019
-609,000.00 USD
Jan 1, 2020
-2.56 M USD
Jan 1, 2021
-6.55 M USD
Jan 1, 2022
-6.46 M USD
Jan 1, 2023
-6.68 M USD
Jan 1, 2024
-12.62 M USD
Jan 1, 2025
-3.96 M USD
The PRF Technologies Operating Cash Flow history
YEAROperating Cash FlowYoY
-3.96 MUSD-68.66%
-12.62 MUSD+88.97%
-6.68 MUSD+3.41%
-6.46 MUSD-1.43%
-6.55 MUSD+156.28%
-2.56 MUSD+319.87%
-609,000.00USD-4.09%
-635,000.00USD-27.01%
-870,000.00USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

PRF Technologies Stock analysis

What does PRF Technologies do? PainReform Ltd. develops reformulated pain therapeutics to extend efficacy, minimize adverse effects, and improve patient convenience. The company focuses on enhancing established pharmaceuticals through its proprietary technology, targeting faster recovery of motor function. Its products are designed for healthcare providers and patients seeking advanced pain management solutions. The business model centers on licensing its reformulation technology to pharmaceutical partners. These partners integrate PainReform's solutions into their existing drug portfolios, leveraging the technology to improve product performance without developing new compounds from scratch. The primary buyers are established pharmaceutical companies looking to extend patent life and enhance market competitiveness of their pain management drugs. PainReform's technology addresses key pain management challenges by prolonging drug effects and reducing side effects. This positions the company as a strategic partner for pharmaceutical firms aiming to optimize their therapeutic offerings. The target segments include chronic pain patients and healthcare systems seeking more effective and safer pain treatment options. PRF Technologies is one of the most popular companies on Eulerpool.

Frequently Asked Questions about PRF Technologies stock

Operating Cash Flow of PRF Technologies is -3.96 M USD in 2025.

Operating Cash Flow of PRF Technologies changed from -12.62 M USD to -3.96 M USD, representing a -68.66% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Operating Cash Flow PRF Technologies since 2006 – with annual values, charts, and detailed analysis.

Operating cash flow measures the cash generated from core business operations. It is a pure measure of a company's ability to generate cash.

Operating Cash Flow's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Operating Cash Flow's PRF Technologies historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — PRF Technologies

All Key Metrics — PRF Technologies